Kenjiro Ono

13.9k total citations · 3 hit papers
227 papers, 10.5k citations indexed

About

Kenjiro Ono is a scholar working on Physiology, Neurology and Molecular Biology. According to data from OpenAlex, Kenjiro Ono has authored 227 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Physiology, 68 papers in Neurology and 53 papers in Molecular Biology. Recurrent topics in Kenjiro Ono's work include Alzheimer's disease research and treatments (122 papers), Parkinson's Disease Mechanisms and Treatments (42 papers) and Cholinesterase and Neurodegenerative Diseases (34 papers). Kenjiro Ono is often cited by papers focused on Alzheimer's disease research and treatments (122 papers), Parkinson's Disease Mechanisms and Treatments (42 papers) and Cholinesterase and Neurodegenerative Diseases (34 papers). Kenjiro Ono collaborates with scholars based in Japan, United States and United Kingdom. Kenjiro Ono's co-authors include Masahito Yamada, Hironobu Naiki, Kazuhiro Hasegawa, David B. Teplow, Tsuyoshi Hamaguchi, Margaret M. Condron, Giulio Maria Pasinetti, Mie Hirohata, Lap Ho and Akihiko Takashima and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Neuroscience.

In The Last Decade

Kenjiro Ono

218 papers receiving 10.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro

2004 1.0k citations Kenjiro Ono, Masahito Yamada et al. profile →
Structure–neurotoxicity relationships of amyloid β-protein oligomers

2009 666 citations Kenjiro Ono, David B. Teplow et al. Proceedings of the National Academy of Sciences profile →
Expression of Concern: Potent anti‐amyloidogenic and fibril‐destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease

2003 587 citations Kenjiro Ono, Masahito Yamada et al. Journal of Neurochemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kenjiro Ono Japan	52	6.0k	3.8k	1.9k	1.4k	1.2k	227	10.5k
Masahito Yamada Japan	59	6.0k 1.0×	4.7k 1.2×	1.6k 0.8×	3.4k 2.4×	2.1k 1.8×	380	13.9k
Gerald Münch Australia	60	4.1k 0.7×	3.3k 0.9×	1.3k 0.7×	766 0.6×	1.9k 1.5×	203	11.3k
Fusheng Yang United States	34	7.7k 1.3×	4.1k 1.1×	2.1k 1.1×	651 0.5×	2.1k 1.7×	56	12.0k
George E. Barreto Colombia	61	2.8k 0.5×	4.2k 1.1×	1.1k 0.6×	1.2k 0.9×	2.2k 1.8×	298	11.8k
Akihiko Nunomura Japan	62	7.3k 1.2×	6.0k 1.6×	2.4k 1.3×	1.2k 0.8×	1.8k 1.5×	112	13.5k
Rukhsana Sultana United States	77	6.2k 1.0×	6.3k 1.7×	2.0k 1.1×	690 0.5×	1.6k 1.3×	146	13.8k
Sally A. Frautschy United States	61	8.3k 1.4×	5.0k 1.3×	2.4k 1.3×	847 0.6×	2.8k 2.3×	117	15.4k
Tamar Amit Israel	53	2.4k 0.4×	2.2k 0.6×	1.8k 0.9×	1.8k 1.3×	1.1k 0.9×	158	9.0k
Hyoung‐gon Lee United States	60	6.2k 1.0×	5.8k 1.5×	1.9k 1.0×	773 0.6×	1.8k 1.5×	167	12.2k
Giulio Maria Pasinetti United States	75	7.0k 1.2×	6.2k 1.6×	2.3k 1.2×	1.4k 1.0×	3.1k 2.6×	326	17.0k

Countries citing papers authored by Kenjiro Ono

Since Specialization

Citations

This map shows the geographic impact of Kenjiro Ono's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenjiro Ono with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenjiro Ono more than expected).

Fields of papers citing papers by Kenjiro Ono

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenjiro Ono. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenjiro Ono. The network helps show where Kenjiro Ono may publish in the future.

Co-authorship network of co-authors of Kenjiro Ono

This figure shows the co-authorship network connecting the top 25 collaborators of Kenjiro Ono. A scholar is included among the top collaborators of Kenjiro Ono based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenjiro Ono. Kenjiro Ono is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Noguchi‐Shinohara, Moeko, Yukiko Mori, Junji Komatsu, et al.. (2025). Lecanemab‐Associated Amyloid‐β Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer's Disease. Annals of Neurology. 97(5). 993–1006. 3 indexed citations

Ostrakhovitch, Elena A., Kenjiro Ono, & Tritia R. Yamasaki. (2025). Metabolomics in Parkinson’s Disease and Correlation with Disease State. Metabolites. 15(3). 208–208. 4 indexed citations

Ono, Kenjiro, Moeko Noguchi‐Shinohara, & Takahiro Watanabe‐Nakayama. (2024). The Basis of Anti-Aβ Antibody Therapy: The Toxicity of Aβ Aggregates and the Mechanism of Action of Anti-Aβ Antibodies. Internal Medicine. 65(1). 41–45. 2 indexed citations

Hirata, Kosei, et al.. (2024). A case of left posterior cortical atrophy presenting with kana-predominant reading impairment. Rinsho Shinkeigaku. 64(8). 557–563.

Furuta, Yoshihiko, Masato Akiyama, Naoki Hirabayashi, et al.. (2024). Common protein-altering variant in GFAP is associated with white matter lesions in the older Japanese population. npj Genomic Medicine. 9(1). 59–59.

Noguchi‐Shinohara, Moeko & Kenjiro Ono. (2024). Anti-amyloid β Antibody Therapies for Alzheimer's Disease: Association between the Target of Amyloid β Aggregates and the Clinical Efficacy of Anti-amyloid β Antibody. Internal Medicine. 65(1). 67–70. 3 indexed citations

Nakajima, Kenichi, Takeshi Matsumura, Junji Komatsu, et al.. (2024). Sympathetic 123I-metaiodobenzylguanidine index for Lewy body disease: probability-based diagnosis and identifying patients exempt from late imaging. Annals of Nuclear Medicine. 38(10). 814–824. 1 indexed citations

Watanabe‐Nakayama, Takahiro, Mayumi Tsuji, Kenichi Umeda, et al.. (2023). Structural Dynamics of Amyloid-β Protofibrils and Actions of Anti-Amyloid-β Antibodies as Observed by High-Speed Atomic Force Microscopy. Nano Letters. 23(13). 6259–6268. 15 indexed citations

Tsuji, Mayumi, Tatsunori Oguchi, Ken Yamamoto, et al.. (2023). The Curcumin Derivative GT863 Protects Cell Membranes in Cytotoxicity by Aβ Oligomers. International Journal of Molecular Sciences. 24(4). 3089–3089. 5 indexed citations

10.

Ono, Kenjiro, Mayumi Tsuji, Tritia R. Yamasaki, & Giulio Maria Pasinetti. (2020). Anti-aggregation Effects of Phenolic Compounds on α-synuclein. Molecules. 25(10). 2444–2444. 25 indexed citations

11.

Watanabe‐Nakayama, Takahiro, Hiroki Konno, Noriyuki Kodera, et al.. (2020). Self- and Cross-Seeding on α-Synuclein Fibril Growth Kinetics and Structure Observed by High-Speed Atomic Force Microscopy. ACS Nano. 14(8). 9979–9989. 36 indexed citations

12.

Ono, Kenjiro, Kishin Koh, Hiroyuki Ishiura, et al.. (2020). A novel mutation in the GBA2 gene in a Japanese patient with SPG46: A case report. eNeurologicalSci. 19. 100238–100238. 4 indexed citations

13.

Kinno, Ryuta, Hirotaka Ochiai, Yukiko Mori, et al.. (2019). The relationship between thyroid function and cerebral blood flow in mild cognitive impairment and Alzheimer’s disease. PLoS ONE. 14(4). e0214676–e0214676. 21 indexed citations

14.

Nagayama, Hiroshi, Osamu Kano, Hidetomo Murakami, et al.. (2018). Effect of istradefylline on mood disorders in Parkinson's disease. Journal of the Neurological Sciences. 396. 78–83. 38 indexed citations

15.

Watanabe‐Nakayama, Takahiro, et al.. (2016). High-speed atomic force microscopy reveals structural dynamics of amyloid β _1–42 aggregates. Proceedings of the National Academy of Sciences. 113(21). 5835–5840. 174 indexed citations

16.

Umeda, Tomohiro, Kenjiro Ono, M. Yamashita, et al.. (2016). Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers. Brain. 139(5). 1568–1586. 100 indexed citations

17.

Takahashi, Ryoichi, Kenjiro Ono, Yusaku Takamura, et al.. (2015). Phenolic compounds prevent the oligomerization of α‐synuclein and reduce synaptic toxicity. Journal of Neurochemistry. 134(5). 943–955. 84 indexed citations

18.

Hirohata, Mie, Kenjiro Ono, Junichi Takasaki, et al.. (2012). Anti-amyloidogenic effects of soybean isoflavones in vitro: Fluorescence spectroscopy demonstrating direct binding to Aβ monomers, oligomers and fibrils. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1822(8). 1316–1324. 33 indexed citations

19.

Ono, Kenjiro, Ryoichi Takahashi, Tokuhei Ikeda, & Masahito Yamada. (2012). Cross‐seeding effects of amyloid β‐protein and α‐synuclein. Journal of Neurochemistry. 122(5). 883–890. 169 indexed citations

20.

Wang, Jun, Kenjiro Ono, Dara L. Dickstein, et al.. (2010). Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. Neurobiology of Aging. 32(12). 2321.e1–2321.e12. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact